|
|
|
|
| | | | USD | EUR | GBP | JPY | 83.34 | 89.43 | 104.26 | 0.53 |
| | | | AED | AUD | CHF | CAD | 17.54 | 49.53 | 64.49 | 50.06 |
| | | | HKD | SAR | SGD | ZAR | 8.28 | 17.22 | 47.46 | 4.57 |
|
|
|
|
|
|
|
|
|
|
|
Industry :
|
Pharmaceuticals & Drugs
|
|
|
|
|
|
|
|
|
|
52-Week-High (Rs.)
|
2782.00
|
|
|
52-Week-Low (Rs.)
|
1599.00
|
|
|
|
|
* BSE PRICES
|
|
|
|
|
Particulars | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Operational & Financial Ratios | | | | | | Earnings Per Share (Rs) | 31.06 | 58.58 | 67.23 | 55.45 | 44.05 | CEPS(Rs) | 50.93 | 47.09 | 51.63 | 45.65 | 39.13 | DPS(Rs) | 22.00 | 48.00 | 35.00 | 32.00 | 17.00 | Book NAV/Share(Rs) | 190.75 | 374.94 | 356.30 | 302.59 | 296.34 | Tax Rate(%) | 33.33 | 32.38 | 16.71 | 15.96 | 20.29 | Margin Ratios | | | | | | Core EBITDA Margin(%) | 31.42 | 30.60 | 33.45 | 30.64 | 27.69 | EBIT Margin(%) | 23.90 | 24.80 | 25.95 | 24.73 | 24.31 | Pre Tax Margin(%) | 20.10 | 21.36 | 20.85 | 17.85 | 16.05 | PAT Margin (%) | 13.40 | 14.44 | 17.37 | 15.00 | 12.80 | Cash Profit Margin (%) | 21.97 | 23.22 | 26.68 | 24.70 | 22.73 | Performance Ratios | | | | | | ROA(%) | 8.75 | 8.66 | 9.66 | 7.87 | 6.25 | ROE(%) | 16.43 | 16.02 | 20.41 | 18.52 | 15.58 | ROCE(%) | 18.10 | 16.94 | 16.30 | 14.68 | 13.46 | Asset Turnover(x) | 0.65 | 0.60 | 0.56 | 0.52 | 0.49 | Sales/Fixed Asset(x) | 0.70 | 0.69 | 0.66 | 0.65 | 0.63 | Working Capital/Sales(x) | 15.15 | 4.55 | 4.21 | 14.49 | 8.81 | Efficiency Ratios | | | | | | Fixed Capital/Sales(x) | 1.43 | 1.45 | 1.51 | 1.54 | 1.58 | Receivable days | 76.09 | 82.04 | 85.05 | 83.57 | 77.19 | Inventory Days | 79.08 | 98.61 | 95.25 | 83.60 | 83.26 | Payable days | 117.53 | 136.79 | 163.65 | 158.89 | 181.40 | Valuation Parameters | | | | | | PER(x) | 49.49 | 23.87 | 18.90 | 17.78 | 22.16 | PCE(x) | 30.19 | 29.69 | 24.61 | 21.59 | 24.95 | Price/Book(x) | 8.06 | 7.46 | 7.13 | 6.52 | 6.59 | Yield(%) | 1.43 | 1.72 | 1.38 | 1.62 | 0.87 | EV/Net Sales(x) | 7.34 | 7.50 | 7.34 | 6.21 | 6.67 | EV/Core EBITDA(x) | 22.16 | 21.95 | 20.49 | 17.78 | 19.26 | EV/EBIT(x) | 30.11 | 29.72 | 27.83 | 24.75 | 27.13 | EV/CE(x) | 4.39 | 4.54 | 4.03 | 3.24 | 3.19 | M Cap / Sales | 6.76 | 7.02 | 6.67 | 5.41 | 5.73 | Growth Ratio | | | | | | Net Sales Growth(%) | 14.13 | 4.52 | 4.57 | 7.04 | 35.77 | Core EBITDA Growth(%) | 10.50 | -0.22 | 7.25 | 7.97 | 60.93 | EBIT Growth(%) | 10.11 | 0.13 | 9.89 | 9.26 | 65.47 | PAT Growth(%) | 6.05 | -12.87 | 21.24 | 25.90 | 54.64 | EPS Growth(%) | -46.97 | -12.87 | 21.24 | 25.90 | 54.64 | Financial Stability Ratios | | | | | | Total Debt/Equity(x) | 0.71 | 0.53 | 0.73 | 1.04 | 1.12 | Current Ratio(x) | 1.15 | 1.62 | 1.60 | 1.13 | 1.21 | Quick Ratio(x) | 0.69 | 0.90 | 0.88 | 0.69 | 0.78 | Interest Cover(x) | 6.30 | 7.21 | 5.09 | 3.59 | 2.94 | Total Debt/Mcap(x) | 0.09 | 0.07 | 0.10 | 0.16 | 0.17 |
|
|
|
|
|
|